Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,173 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Current Role of the Heavy/Light Chain Assay in the Diagnosis, Prognosis and Monitoring of Multiple Myeloma: An Evidence-Based Approach.
Ríos-Tamayo R, Puig N, Algarín M, García de Veas Silva JL, Barbosa N, Encinas C, Hernández JÁ, Alonso R, Campos ML, Rodríguez T, Leivas A, Olivares MJ, Sánchez MJ, Paiva B, Lahuerta JJ, Martínez-López J. Ríos-Tamayo R, et al. Among authors: alonso r. Diagnostics (Basel). 2021 Oct 30;11(11):2020. doi: 10.3390/diagnostics11112020. Diagnostics (Basel). 2021. PMID: 34829367 Free PMC article. Review.
Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma.
Martinez-Lopez J, Sanchez-Vega B, Barrio S, Cuenca I, Ruiz-Heredia Y, Alonso R, Rapado I, Marin C, Cedena MT, Paiva B, Puig N, Mateos MV, Ayala R, Hernández MT, Jimenez C, Rosiñol L, Martínez R, Teruel AI, Gutiérrez N, Martin-Ramos ML, Oriol A, Bargay J, Bladé J, San-Miguel J, Garcia-Sanz R, Lahuerta JJ. Martinez-Lopez J, et al. Among authors: alonso r. Leukemia. 2017 Jun;31(6):1446-1449. doi: 10.1038/leu.2017.58. Epub 2017 Feb 17. Leukemia. 2017. PMID: 28210002 Free PMC article. Clinical Trial. No abstract available.
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Ruiz-Heredia Y, Sánchez-Vega B, Onecha E, Barrio S, Alonso R, Martínez-Ávila JC, Cuenca I, Agirre X, Braggio E, Hernández MT, Martínez R, Rosiñol L, Gutierrez N, Martin-Ramos M, Ocio EM, Echeveste MA, de Oteyza JP, Oriol A, Bargay J, Gironella M, Ayala R, Bladé J, Mateos MV, Kortum KM, Stewart K, García-Sanz R, Miguel JS, Lahuerta JJ, Martinez-Lopez J. Ruiz-Heredia Y, et al. Among authors: alonso r. Haematologica. 2018 Nov;103(11):e544-e548. doi: 10.3324/haematol.2018.188839. Epub 2018 Jun 28. Haematologica. 2018. PMID: 29954938 Free PMC article. Clinical Trial. No abstract available.
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Alonso R, et al. Blood Adv. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. Blood Adv. 2020. PMID: 32433744 Free PMC article.
The clinical significance of stringent complete response in multiple myeloma is surpassed by minimal residual disease measurements.
Cedena MT, Martin-Clavero E, Wong S, Shah N, Bahri N, Alonso R, Barcenas C, Valeri A, Salazar Tabares J, Sanchez-Pina J, Cuellar C, Martin T, Wolf J, Lahuerta JJ, Martinez-Lopez J. Cedena MT, et al. Among authors: alonso r. PLoS One. 2020 Aug 31;15(8):e0237155. doi: 10.1371/journal.pone.0237155. eCollection 2020. PLoS One. 2020. PMID: 32866200 Free PMC article.
Natural killer cells efficiently target multiple myeloma clonogenic tumor cells.
Leivas A, Risueño RM, Guzmán A, Sánchez-Vega L, Pérez M, Megías D, Fernández L, Alonso R, Pérez-Martínez A, Rapado I, Martínez-López J. Leivas A, et al. Among authors: alonso r. Cancer Immunol Immunother. 2021 Oct;70(10):2911-2924. doi: 10.1007/s00262-021-02901-y. Epub 2021 Mar 10. Cancer Immunol Immunother. 2021. PMID: 33693963 Free PMC article.
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Martinez-Lopez J, Alonso R, Wong SW, Rios R, Shah N, Ruiz-Heredia Y, Sanchez-Pina JM, Sanchez R, Bahri N, Zamanillo I, Poza M, Buenache N, Encinas C, Juarez L, Miras F, Collado L, Barrio S, Martin T, Cedena MT, Wolf J. Martinez-Lopez J, et al. Among authors: alonso r. J Hematol Oncol. 2021 Aug 17;14(1):126. doi: 10.1186/s13045-021-01135-w. J Hematol Oncol. 2021. PMID: 34404440 Free PMC article.
1,173 results